Serum Phenytoin concentrations before and after the addition of thioridazine were retrospectively compared in 27 adults to determine if an interaction occurred between these two drugs. A change in the serum phenytoin concentration of ± 4 μg/ml was considered clinically significant; by this definition four patients (14.8 percent) had an increase, two (7.4 percent) had a decrease, and most (77.8 percent) demonstrated no change. The mean difference was 0.8 μg/ml ± 3.7 μg/ml and was not found to be statistically significant (p < 0.1). Clinically important alterations in phenytoin serum concentration as caused by thioridazine appear to be infrequent.
BochnerFHooperWDTyrerJHGadieMJ. Effect of dosage increments on blood phenytoin concentrations. J Neurol Neurosurg Psychiatry1972; 35: 873–6.
2.
HoughtonGWTichensA. Inhibition of phenytoin metabolism by other drugs used in epilepsy. Int J Clin Pharmacol Biopharm1975; 12: 210–6.
3.
KuttHMcDowellF. Management of epilepsy with diphenylhydantoin sodium: dosage regulation for problem patients. JAMA1968; 203: 969–72.
4.
WoodburryDM, ed. Antiepileptic drugs. New York: Raven Press, 1972.
5.
GaultieriCTPowellSF. Psychoactive drug interactions. J Clin Psychiatry1978; 39: 720–9.
6.
VincentFM. Phenothiazine-induced phenytoin intoxication. Ann Intern Med1980; 93: 56–7.
7.
LinnoilaMViukariMVaisanenKAuvinenJ. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry1980; 137: 819–21.
8.
Evaluation of drug interactions. 2nd ed.Washington, DC: American Pharmaceutical Association, 1976.
9.
LivingstonSBermanWPauliLL. Anticonvulsant drug blood levels. JAMA1975; 232: 60–2.
10.
KuttH. Interactions of antiepileptic drugs. Epilepsia1975; 15: 393–402.
11.
RischSCGroomGPJanowskyDS. Interfaces of psychopharmacology and cardiology. Part 2. J Clin Psychiatry1981; 42: 47–52.
12.
SirisJNPippengerCEWernerWLMaslandRL. Anticonvulsant drug serum levels in psychiatric patients with seizure disorders. NY State J Med1974; 74: 1554–6.
13.
ByckR. Drugs and the treatment of psychiatric disorders. In: GilmanAGGoodmanLSGilmanA, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 5th ed. New York: Macmillan, 1975: 152–200.
14.
AxelssonR. On the serum concentration and antipsychotic effects of thioridazine, thioridazine side chain sulfoxide and thioridazine side chain sulfone in chronic psychiatric patients. Curr Ther Res1977; 21: 587–605.
15.
CrammerJL. Antipsychotic agents, thioridazine: pharmacokinetics, plasma levels, and clinical response. In: BurrowsGDNormanTR, eds. Psychotropic drugs: plasma concentration and clinical response. New York: Marcel Dekker, 1981: 303–16.
16.
FrainMM. Preliminary report on Mellaril in epilepsy. Am J Psychiatry1960; 117: 547–8.
17.
PanicPMDelucaMAOsterheldRG. Thioridazine in the treatment of behavior disorders in epileptics. Am J Psychiatry1961; 117: 832–3.
18.
KammIMandelA. Thioridazine in the treatment of behavior disorders in epileptics. Dis Nerv Syst1967; 28: 46–8.
19.
GotzVPYostRLLamadridMEBuchananCD. Evaluation of a potential interaction: thioridazine-phenytoin. Hosp Pharm1984; 19: 555–7.
20.
BuchananRAKinkelAWGouletJRSmithTC. The metabolism of diphenylhydantoin following once-daily administration. Neurology1972; 22: 126–30.
21.
MarksRG. Designing a research project: the basis of biomedical research methodology. Belmont, CA: Lifetime Learning Publications, 1982.
22.
FinnALOlanowCW. Phenytoin: therapeutic use and serum concentration monitoring. In: TaylorWJFinnAL, eds. Individualizing drug therapy: practical application of drug monitoring. Vol 2. New York: Gross, Townsend, Frank, 1981: 63–85.
23.
Physicians desk reference. Oradell, NJ: Medical Economics, 1986.
24.
HaidukewyckDRodinEA. Effects of phenothiazines on serum antiepileptic drug concentrations in psychiatric patients with seizure disorders. Ther Drug Monit1985; 7: 401–5.
